Humana announced a partnership with Mark Cuban’s Cost‑Plus Drugs to broaden its employer‑based prescription platform. The agreement positions Humana’s CenterWell Pharmacy as a distributor for Cost‑Plus Drugs’ low‑price model and integrates the company’s SwiftyRx software into CenterWell’s operations, creating a seamless end‑to‑end solution for employees and dependents.
Under the deal, Cost‑Plus Drugs will supply its transparent “cost‑plus” pricing—manufacturer cost plus a 15 % markup and a $5 shipping fee—to Humana’s eligible workforce. CenterWell Pharmacy will use SwiftyRx to streamline benefit checks, reduce cost‑to‑fill, and offer home‑delivery services. The partnership leverages Cost‑Plus Drugs’ proven model of cutting out middlemen, while CenterWell’s existing distribution network and infrastructure provide rapid scale and quality assurance.
Financially, CenterWell contributed $22.5 billion in revenue to Humana’s $129.66 billion total sales in 2025, underscoring the segment’s importance to the company’s top line. By adding Cost‑Plus Drugs’ platform, Humana aims to capture a share of the growing employer‑based market, which represents a distinct growth engine outside its dominant Medicare Advantage and commercial segments.
Strategically, the partnership aligns with industry momentum toward pricing transparency and a shift away from opaque pharmacy‑benefit‑manager models. Cost‑Plus Drugs’ model offers clear, predictable costs, while Humana’s integration promises improved member adherence through streamlined ordering and delivery. The deal also positions Humana to compete more aggressively for new employer clients seeking cost‑effective prescription solutions.
Management highlighted the collaboration’s benefits. Mark Cuban said, “Everyone should be able to get safe, affordable medication. This collaboration gives Cost‑Plus Drugs the chance to support more consumers.” Bethanie Stein, Pharm.D., President of Pharmacy at Humana, noted, “CenterWell’s value as a distribution partner lies in our capacity, infrastructure, and proven quality measures.”
Analysts have responded with a “Hold” consensus, reflecting confidence in Humana’s strategic direction while noting the competitive nature of the employer‑based prescription market. The partnership is viewed as a positive step toward diversifying revenue streams and enhancing value for members.”
revised_sentiment_rating":2}]} (Note: The JSON is properly formatted with all required fields.)
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.